<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02952885</url>
  </required_header>
  <id_info>
    <org_study_id>CCHIK-01</org_study_id>
    <nct_id>NCT02952885</nct_id>
  </id_info>
  <brief_title>Strict IGF-1 Control in Acromegaly</brief_title>
  <acronym>I-Con</acronym>
  <official_title>Strict IGF-1 Control in Acromegaly (I-Con Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Michael's Hospital, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acromegaly is a rare, chronic, and debilitating disease, usually caused by a benign tumor on
      the pituitary gland, which leads to excessive production of growth hormone (GH). GH excess in
      turn causes overproduction of another hormone called insulin-like growth factor-1 (IGF-1).
      IGF-1 levels are currently the most widely accepted measure of disease activity.

      In Canada, medical therapy with a type of medicine called &quot;somatostatin analogues&quot; (SSA),
      such as octreotide and lanreotide, is recommended for treatment of acromegaly. However,
      studies have shown that a significant number of patients who take SSA medications alone
      remain with elevated levels of IGF-1 in their blood.

      Another medication that is used to treat acromegaly is pegvisomant (PEGV), and the
      investigators plan to study whether strict control of IGF-1, by adding or optimizing the use
      of PEGV, results in a significant health benefits to patients who still have modestly high
      levels of IGF-1 in their blood.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2017</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Health Related Quality of Life (AcroQoL)</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum IGF-1 level</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acromegaly Disease Activity Tool (ACRODAT)</measure>
    <time_frame>six months</time_frame>
    <description>To assess acromegaly co-morbidities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-assessed Acromegaly Symptom Questionnaire</measure>
    <time_frame>six months</time_frame>
    <description>To assess acromegaly signs and symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>Pegvisomant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label, non-randomized single arm variable dose study of pegvisomant conducted in a real world setting.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegvisomant</intervention_name>
    <description>Study medications will be prescribed as per clinical practice with PEGV being added, or optimally dosed, at the Month 0 visit. Subjects who are naïve to PEGV should start their daily injections at 10 mg / day if used as combination therapy or 20 mg / day if used as monotherapy. Maximum dosing should not exceed 40mg/day. Dosing of PEGV can be adjusted as per clinical judgement to meet the normalization of IGF-1 levels (&lt;1.0 ULN) in increments of 5-10mg/day. In the event of a reduction in IGF-1 below the LLN, the dose of PEGV could be decreased by 5-10 mg/day.</description>
    <arm_group_label>Pegvisomant</arm_group_label>
    <other_name>Somavert</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (at least 18 years old) with confirmed acromegaly who have been on a
             stable dose of SSA monotherapy, or combination therapy with sub-optimal dose of
             pegvisomant for at least 6 months and whose IGF-I levels are persistently but modestly
             (1.0 ULN&lt; [IGF1 serum level] &gt; 1.3 ULN) elevated will be included.

        Exclusion Criteria:

          -  Visual field loss or optic chiasmal compression or pituitary tumors within 3 mm from
             the chiasm will not be included

          -  Cranial nerve palsies or intracranial hypertension requiring tumour decompression
             surgery

          -  Clinically significant hepatic disease and/or elevated liver enzymes (ALT, AST &gt; 3 x
             ULN)

          -  Patients who have received pituitary surgery within one year prior to screening visit

          -  Patients who have received radiation therapy within one year prior to screening visit

          -  History of hypersensitivity to any components of Pegvisomant

          -  Inability to fully comprehend the nature of the study or cooperate with study
             procedures

          -  Pregnant / lactating women and subjects refusing to use adequate contraception to
             prevent pregnancy during the study.

          -  Subjects unwilling or unable to self-administer medication on a daily basis

          -  Known or suspected alcohol / drug abuse

          -  Severe acute or chronic medical or psychiatric condition or laboratory abnormality
             that could increase the risk associated with trial participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Constance Chik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, Toronto, ON</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominic Lee</last_name>
    <phone>416-864-6060</phone>
    <phone_ext>77058</phone_ext>
    <email>leekih@smh.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Judith Hall</last_name>
    <phone>416-864-6060</phone>
    <phone_ext>7121</phone_ext>
    <email>hallju@smh.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Joseph Health Care London</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah De Brabandere</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>56399</phone_ext>
      <email>sarah.debrabandere@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Stan Van Uum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laya Fayyazi</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>35378</phone_ext>
      <email>Laya.Fayyazi@MUHC.MCGILL.CA</email>
    </contact>
    <investigator>
      <last_name>Juan Andres Rivera Ramirez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Québec-Université Laval</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Christine Dubé</last_name>
      <phone>418-525-4444</phone>
      <phone_ext>47904</phone_ext>
      <email>Marie-Christine.Dube@crchudequebec.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Marie-Claire Denis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Ève Domingue, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Melmed S. Medical progress: Acromegaly. N Engl J Med. 2006 Dec 14;355(24):2558-73. Review. Erratum in: N Engl J Med. 2007 Feb 22;356(8):879.</citation>
    <PMID>17167139</PMID>
  </reference>
  <reference>
    <citation>Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009 Nov;119(11):3189-202. doi: 10.1172/JCI39375. Epub 2009 Nov 2. Review.</citation>
    <PMID>19884662</PMID>
  </reference>
  <reference>
    <citation>Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update. Endocr Pract. 2011 Jul-Aug;17 Suppl 4:1-44.</citation>
    <PMID>21846616</PMID>
  </reference>
  <reference>
    <citation>Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S, Melmed S. Clinical, quality of life, and economic value of acromegaly disease control. Pituitary. 2011 Sep;14(3):284-94. doi: 10.1007/s11102-011-0310-7. Review.</citation>
    <PMID>21597975</PMID>
  </reference>
  <reference>
    <citation>Neggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA, Badia X, Webb SM, van der Lely AJ. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab. 2008 Oct;93(10):3853-9. doi: 10.1210/jc.2008-0669. Epub 2008 Jul 22.</citation>
    <PMID>18647806</PMID>
  </reference>
  <reference>
    <citation>Carmichael JD, Bonert VS, Nuño M, Ly D, Melmed S. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab. 2014 May;99(5):1825-33. doi: 10.1210/jc.2013-3757. Epub 2014 Feb 25.</citation>
    <PMID>24606084</PMID>
  </reference>
  <reference>
    <citation>Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000 Apr 20;342(16):1171-7.</citation>
    <PMID>10770982</PMID>
  </reference>
  <reference>
    <citation>van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001 Nov 24;358(9295):1754-9.</citation>
    <PMID>11734231</PMID>
  </reference>
  <reference>
    <citation>Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab. 2007 Dec;92(12):4598-601. Epub 2007 Sep 25.</citation>
    <PMID>17895318</PMID>
  </reference>
  <reference>
    <citation>Jørgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LØ, Hagen C, Ørskov H. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab. 2005 Oct;90(10):5627-31. Epub 2005 Jul 26.</citation>
    <PMID>16046586</PMID>
  </reference>
  <reference>
    <citation>Neggers SJ, de Herder WW, Janssen JA, Feelders RA, van der Lely AJ. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol. 2009 Apr;160(4):529-33. doi: 10.1530/EJE-08-0843. Epub 2009 Jan 13.</citation>
    <PMID>19141604</PMID>
  </reference>
  <reference>
    <citation>De Marinis L, Bianchi A, Fusco A, Cimino V, Mormando M, Tilaro L, Mazziotti G, Pontecorvi A, Giustina A. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA. Pituitary. 2007;10(3):227-32.</citation>
    <PMID>17484056</PMID>
  </reference>
  <reference>
    <citation>Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, van der Lely AJ. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet. 2005 May 7-13;365(9471):1644-6. Erratum in: Lancet. 2005 May;365(9471):1620.</citation>
    <PMID>15885297</PMID>
  </reference>
  <reference>
    <citation>Trainer PJ, Ezzat S, D'Souza GA, Layton G, Strasburger CJ. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf). 2009 Oct;71(4):549-57. doi: 10.1111/j.1365-2265.2009.03620.x. Epub 2009 May 2.</citation>
    <PMID>19438906</PMID>
  </reference>
  <reference>
    <citation>Neggers SJ, Kopchick JJ, Jørgensen JO, van der Lely AJ. Hypothesis: Extra-hepatic acromegaly: a new paradigm? Eur J Endocrinol. 2011 Jan;164(1):11-6. doi: 10.1530/EJE-10-0969. Epub 2010 Nov 2.</citation>
    <PMID>21045065</PMID>
  </reference>
  <reference>
    <citation>Neggers SJ, van der Lely AJ. Pegvisomant and improvement of quality of life in acromegalic patients. Horm Res Paediatr. 2011;76 Suppl 1:102-5. doi: 10.1159/000329189. Epub 2011 Jul 21.</citation>
    <PMID>21778759</PMID>
  </reference>
  <reference>
    <citation>Neggers SJ, Biermasz NR, van der Lely AJ. What is active acromegaly and which parameters do we have? Clin Endocrinol (Oxf). 2012 May;76(5):609-14. doi: 10.1111/j.1365-2265.2012.04346.x. Review.</citation>
    <PMID>22268623</PMID>
  </reference>
  <reference>
    <citation>Badia X, Webb SM, Prieto L, Lara N. Acromegaly Quality of Life Questionnaire (AcroQoL). Health Qual Life Outcomes. 2004 Feb 27;2:13.</citation>
    <PMID>14987332</PMID>
  </reference>
  <reference>
    <citation>Lin HM, Hughes MD. Adjusting for regression toward the mean when variables are normally distributed. Stat Methods Med Res. 1997 Jun;6(2):129-46.</citation>
    <PMID>9261912</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2016</study_first_submitted>
  <study_first_submitted_qc>October 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2016</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Michael's Hospital, Toronto</investigator_affiliation>
    <investigator_full_name>Constance Chik</investigator_full_name>
    <investigator_title>Affiliate Scientist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

